Chirag K. Patel - Mar 4, 2024 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
President & Co-CEO, Director
Signature
/s/ Denis Butkovic, Attorney-in-Fact
Stock symbol
AMRX
Transactions as of
Mar 4, 2024
Transactions value $
$0
Form type
4
Date filed
3/6/2024, 05:39 PM
Previous filing
Nov 8, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Award $0 +370K $0.00 370K Mar 4, 2024 Class A Common Stock 370K Direct F1, F2
transaction AMRX Performance-Based Restricted Stock Units Award $0 +1.33M $0.00 1.33M Mar 4, 2024 Class A Common Stock 1.33M Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 The restricted stock units vest in four equal annual installments beginning on March 4, 2025.
F3 Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F4 Represents a performance-based restricted stock unit grant of 666,667 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period.

Remarks:

Exhibit 24 attached - Power of Attorney